Advertisement

Topics

Wales backs NHS use of Actelion’s Uptravi for PAH

07:07 EDT 14 Jun 2018 | PharmaTimes

Some patients with pulmonary arterial hypertension (PAH) are now able to access Actelion’s selexipag on the NHS in Wales after a green light from the All Wales Medicines Strategy Group (AWMSG).

Original Article: Wales backs NHS use of Actelion’s Uptravi for PAH

NEXT ARTICLE

More From BioPortfolio on "Wales backs NHS use of Actelion’s Uptravi for PAH"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pulmonary Hypertension
Pulmonary arterial hypertension (PAH) is a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs of affected individuals. Symptoms can range from mild breathles...